Mattsson-Carlgren, Niklas http://orcid.org/0000-0002-8885-7724
Palmqvist, Sebastian
Blennow, Kaj http://orcid.org/0000-0002-1890-4193
Hansson, Oskar http://orcid.org/0000-0001-8467-7286
Article History
Received: 6 May 2020
Accepted: 9 November 2020
First Online: 7 December 2020
Change Date: 4 January 2021
Change Type: Correction
Change Details: A Correction to this paper has been published: https://doi.org/10.1038/s41467-020-20693-0.
Competing interests
: N.M.C. and S.P. report no competing interest. K.B. has served as a consultant or at advisory boards for Abcam, Axon, Biogen, Lilly, MagQu, Novartis and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg. O.H. has acquired research support (for the institution) from Roche, Pfizer, GE Healthcare, Biogen, AVID Radiopharmaceuticals and Euroimmun. In the past 2 years, he has received consultancy/speaker fees (paid to the institution) from Biogen and Roche.